Vertex Pharmaceuticals Incorporated (BVMF:VRTX34)

Brazil flag Brazil · Delayed Price · Currency is BRL
576.26
+15.80 (2.82%)
At close: Nov 11, 2025
2.82%
Market Cap583.40B
Revenue (ttm)62.48B
Net Income (ttm)19.59B
Shares Outn/a
EPS (ttm)75.80
PE Ratio29.79
Forward PE21.30
Dividendn/a
Ex-Dividend Daten/a
Volume507
Average Volume139
Open571.71
Previous Close560.46
Day's Range571.71 - 576.26
52-Week Range497.63 - 745.00
Beta0.32
RSI51.80
Earnings DateNov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1989
Employees 6,100
Stock Exchange Brazil Stock Exchange
Ticker Symbol VRTX34
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.